CD7 Specific Neutra™ Antibody Products

CD7 molecule, also known as GP40, is a 40 kDa membrane protein belonging to the immunoglobulin superfamily. CD7 is normally expressed on 85% of peripheral blood T cells and NK cells as well as their precursor cells, which serves as a co-stimulatory receptor aiding in T cell activation and engaging with various immune subsets. Its presence has been linked to disease aggressiveness, drug resistance, and unfavorable prognosis.

Its Gene ID: 924, UniProtKB ID: P09564, and OMIM ID: 186820.

CD7 in Immune Cells

CD7 and CD3 are potent signaling molecules that work together to stimulate mitosis. They are essential for activating and proliferating T cells in peripheral blood mononuclear cells (PBMCs) and for the expression of IL-2Rα. CD7 activation also leads to the release of cytokines like IL-2, TNF-α, and TNF-β by T cells. In addition, CD7 can also mediate the transmembrane flow of calcium ions in NK cells. Treating NK cells with a CD7 monoclonal antibody (mAb) can enhance surface antigen expression, boost γ-interferon secretion, and improve NK cytotoxicity and its adhesion to fibronectin.

CD7 in T Cell Malignancies

CD7 is significantly upregulated in tumor cells of T-cell lymphoma, acute T-lymphoblastic leukemia (T-ALL), and acute myeloid leukemia (AML), making it a promising target for the treatment of T-cell malignancies. CD7 antibodies or antibody derivatives can attach to the CD7 antigen on the surface of the tumor cells, triggering rapid internalization of the antibody-CD7 complex into the cytoplasm. This process induces apoptosis, hinders cell proliferation, and enhances cytotoxicity.

CD7 in CAR-T Cell Therapy

Chimeric antigen receptor T-cell therapy (CAR-T) stands as a groundbreaking cell-based immunotherapy that has exhibited significant efficacy in recent years. The utilization of anti-CD7 CAR-T cells in T-cell lymphoma treatment has emerged as a promising therapeutic approach. However, the presence of CD7 on the surface of CAR-T cells triggers their premature elimination, hindering their proliferation within patients and compromising their tumor-killing potential. To address this issue, the development of CAR-T cells targeting CD7 necessitates the inhibition of CD7 on T lymphocyte membranes. Currently, the strategies used to avoid this phenomenon include the following.

• Using CRISPR-Cas9 gene editing technology to remove genes that regulate CD7 expression.
• Anchoring CD7 protein in the endoplasmic reticulum and/or Golgi apparatus using a protein blocking agent (PEBL) consisting of an anti-CD7 single-chain variable fragment (scFv) and an intracellularly retained structural domain.
• Using a recombinant anti-CD7 mAb containing the same binding domain as the CAR blocks the CD7 antigen on the surface of T cells.

There have been several CD7 CAR-T cells entering clinical trials, which have shown efficacy in the therapy of T-ALL.

Fig.1 Preparation methods of anti-CD7 CAR-T cells.¹

Creative Biolabs offers high-quality anti-CD7 antibody products that can be used for various immunodiagnostics. Additionally, we provide customization services for developing antibody-drug conjugates based on CD7.

REFERENCE

1. Liu, Jile, et al. "Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances." Frontiers in Immunology 14 (2023): 1170968. Distributed under open access license CC BY 4.0, without modification.